- Home
- TCBS vs KLRS Comparison
TCBS vs KLRS Comparison
Compare TCBS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- KLRS
- Stock Information
- Founded
- TCBS 1934
- KLRS 2019
- Country
- TCBS United States
- KLRS United States
- Employees
- TCBS N/A
- KLRS N/A
- Industry
- TCBS Banks
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCBS Finance
- KLRS Health Care
- Exchange
- TCBS Nasdaq
- KLRS Nasdaq
- Market Cap
- TCBS 48.7M
- KLRS 46.0M
- IPO Year
- TCBS N/A
- KLRS N/A
- Fundamental
- Price
- TCBS $16.11
- KLRS $7.68
- Analyst Decision
- TCBS
- KLRS Strong Buy
- Analyst Count
- TCBS 0
- KLRS 2
- Target Price
- TCBS N/A
- KLRS $23.00
- AVG Volume (30 Days)
- TCBS 4.3K
- KLRS 224.3K
- Earning Date
- TCBS 11-12-2025
- KLRS 11-15-2025
- Dividend Yield
- TCBS 0.99%
- KLRS N/A
- EPS Growth
- TCBS N/A
- KLRS N/A
- EPS
- TCBS 0.80
- KLRS N/A
- Revenue
- TCBS $14,831,000.00
- KLRS N/A
- Revenue This Year
- TCBS N/A
- KLRS N/A
- Revenue Next Year
- TCBS N/A
- KLRS N/A
- P/E Ratio
- TCBS $20.23
- KLRS N/A
- Revenue Growth
- TCBS 51.57
- KLRS N/A
- 52 Week Low
- TCBS $14.79
- KLRS $2.14
- 52 Week High
- TCBS $19.40
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- TCBS 47.36
- KLRS 67.13
- Support Level
- TCBS $16.10
- KLRS $4.41
- Resistance Level
- TCBS $16.23
- KLRS $8.80
- Average True Range (ATR)
- TCBS 0.19
- KLRS 0.89
- MACD
- TCBS -0.04
- KLRS 0.23
- Stochastic Oscillator
- TCBS 5.40
- KLRS 69.46
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.